The epigenetics of multiple myeloma and the rationale for HDAC inhibitors
Comparing continuous and fixed duration myeloma treatment with triplets and doublets
Can 7+3 as induction therapy for acute myeloid leukemia (AML) be optimized?
The impact of new drugs and the changing role of transplants in multiple myeloma
Advances in acute myeloid leukemia (AML) treatment – updating 7+3